未登录 分享 收藏
分享 收藏
A randomised, double-blind, dose-finding, phase II multicentre study of ODX in the treatment of patients with castration-resistant prostate cancer and skeletal metastases Thellenberg-Karlsson, Camilla; Vjaters, Egils; Kase, Marju; Tammela, Teuvo; Ojamaa, Kristiina; Norming, Ulf; Nyman, Claes; Andersson, Sven-Olof; Hublarovs, Oleg; Marquez-Holmberg, Marcela; Castellanos, Enrique; Ullen, Anders; Holmberg, Anders; Nilsson, Sten 分享 收藏
分享 收藏
分享 收藏
分享 收藏
分享 收藏
Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program Heidenreich, Axel; Gillessen, Silke; Heinrich, Daniel; Keizman, Daniel; O'Sullivan, Joe M.; Carles, Joan; Wirth, Manfred; Miller, Kurt; Reeves, John; Seger, Monica; Nilsson, Sten; Saad, Fred 分享 收藏
分享 收藏
Three-year Safety of Radium-223 Dichloride in Patients with Castration-resistant Prostate Cancer and Symptomatic Bone Metastases from Phase 3 Randomized Alpharadin in Symptomatic Prostate Cancer Trial Parker, Christopher C.; Coleman, Robert E.; Sartor, Oliver; Vogelzang, Nicholas J.; Bottomley, David; Heinrich, Daniel; Helle, Svein I.; O'Sullivan, Joe M.; Fossa, Sophie D.; Chodacki, Ales; Wiechno, Pawel; Logue, John; Seke, Mihalj; Widmark, Anders; Johannessen, Dag Clement; Hoskin, Peter; James, Nicholas D.; Solberg, Arne; Syndikus, Isabel; Kliment, Jan; Wedel, Steffen; Boehmer, Sibylle; Dall'Oglio, Marcos; Franzen, Lars; Bruland, Oyvind S.; Petrenciuc, Oana; Staudacher, Karin; Li, Rui; Nilsson, Sten 分享 收藏
分享 收藏
An exploratory analysis of alkaline phosphatase, lactate dehydrogenase, and prostate-specific antigen dynamics in the phase 3 ALSYMPCA trial with radium-223 Sartor, O.; Coleman, R. E.; Nilsson, S.; Heinrich, D.; Helle, S. I.; O'Sullivan, J. M.; Vogelzang, N. J.; Bruland, O.; Kobina, S.; Wilhelm, S.; Xu, L.; Shan, M.; Kattan, M. W.; Parker, C. 分享 收藏
RELATIONSHIP BETWEEN QUALITY OF LIFE AND OVERALL SURVIVAL IN METASTATIC CASTRATION-RESISTANT PROSTATE CANCER PATIENTS IN ALSYMPCA: ANALYSIS BY PRIOR DOCETAXEL SUBGROUP Shore, Neal D.; Nilsson, Sten; Sartor, Oliver; Vogelzang, Nicholas J.; Coleman, Robert E.; O'Sullivan, Joe M.; Heinrich, Daniel; Bottomley, David; Hoskin, Peter; Franzen, Lars; Solberg, Arne; Reuning-Scherer, Jonathan; Zhan, Lin; Parker, Christopher 分享 收藏
分享 收藏
Efficacy and Safety of Radium-223 Dichloride in Symptomatic Castration-resistant Prostate Cancer Patients With or Without Baseline Opioid Use From the Phase 3 ALSYMPCA Trial Parker, Christopher; Finkelstein, Steven E.; Michalski, Jeff M.; O'Sullivan, Joe M.; Bruland, Oyvind; Vogelzang, Nicholas J.; Coleman, Robert E.; Nilsson, Sten; Sartor, Oliver; Li, Rui; Seger, Monica A.; Bottomley, David 分享 收藏
Radium-223 with concomitant bone-targeting agents in metastatic castration-resistant prostate cancer (CRPC) patients treated in an international early access program (EAP) Saad, F.; Heidenreich, A.; Heinrich, D.; Keizman, D.; O'Sullivan, J. M.; Carles, J.; Wirth, M.; Miller, K.; Gratt, J.; Seger-Van Tol, M.; Nilsson, S.; Gillessen, S. 分享 收藏
Changes in alkaline phosphatase (ALP) dynamics and overall survival (OS) in metastatic castration-resistant prostate cancer (mCRPC) patients treated with radium-223 in an international early access program (EAP) Heinrich, D.; Gillessen, S.; Heidenreich, A.; Keizman, D.; O'Sullivan, J. M.; Carles, J.; Wirth, M.; Miller, K.; Procopio, G.; Gratt, J.; Seger-Van Tol, M.; Nilsson, S.; Saad, F. 分享 收藏
Analysis of overall survival by number of radium-223 injections received in an international expanded access program (iEAP) Paganelli, G.; Procopio, G.; Cabria, M.; Cortesi, E.; Tucci, M.; Farnesi, A.; Mango, L.; Baldari, S.; Hamzaj, A.; Caffo, O.; Marchetti, P.; Dalla Pozza, F.; Zucali, P. A.; Saad, F.; Nilsson, S.; Heinrich, D. 分享 收藏
分享 收藏
Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study Nilsson, S.; Cislo, P.; Sartor, O.; Vogelzang, N. J.; Coleman, R. E.; O'Sullivan, J. M.; Reuning-Scherer, J.; Shan, M.; Zhan, L.; Parker, C. 分享 收藏